ROCKVILLE, MD, June 16, 2025 – uBriGene Biosciences, a leading cell and gene therapy CDMO, is proud to announce the launch of its fully characterized, ready-to-use induced pluripotent stem cell (iPSC) banks. Developed using uBriGene’s proprietary RNA-LNP reprogramming technology, these iPSC banks are now available to support research, translational development, and clinical applications worldwide. [Read more…]
How to Find a Stem Cell Clinical Trial for Your Condition
Are you or a loved on suffering from arthritis, multiple sclerosis (MS), COPD, Alzheimer’s disease, asthma, or other chronic condition? If so, how do you find a stem cell clinical trial?
This article provides the answers, including links to find a clinical trials near you, as well as links to clinical trials for specific conditions.Â
The Science of Cellular Renewal: Urolithin A and the Mitochondrial Revolution
Mitochondria, often called the powerhouses of the cell, play a crucial role in energy production, cellular repair, and metabolic health. Yet, with age, mitochondrial function naturally declines. This leads to reduced energy output, increased oxidative stress, and impaired cellular regeneration, factors that contribute to aging at every level of the body. [Read more…]
iPSC Technology Grows Even More Powerful and Disruptive
Since the discovery and development of induced pluripotent stem cell (iPSC or iPS cell) technology a decade ago, significant progress has been made within stem cell biology and regenerative medicine. In recent years, iPSCs have been used extensively in disease modeling, drug discovery, and cell therapy applications. Importantly, new pathological mechanisms have been identified and explained, new drugs identified by iPSC screens are in the pipeline, and clinical trials employing human iPSC-derived cell types have been initiated. [Read more…]
Vita Therapeutics and I Peace announced a development program to generate iPS- derived differentiated cells for transplant therapy with an initial focus on FSHD (Facioscapulohumeral Muscular Dystrophy) using universal iPS cells
Palo Alto, CA, July 10, 2025 –Â Leading GMP cell CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the company has agreed with Vita Therapeutics (Vita) to jointly develop universal iPS cells that will be used for cell transplantation therapy.
GMP-grade iPS cells will be modified with proprietary, licensed gene editing technology to make a base platform hypoimmune line where Class I and II HLA genes that determine rejection have been depleted. These hypoimmune lines can be further customized in I Peace cGMP facilities. [Read more…]
- « Previous Page
- 1
- …
- 53
- 54
- 55
- 56
- 57
- …
- 336
- Next Page »